The Welsh company’s £14m plant in Tredegar, UK opened its doors earlier this year offering 15,000sq ft of clinical and commercial solid dose manufacturing and the ability to handle potent APIs. With this second investment the firm has added specific tablet manufacturing and coating capacity.
“We are making this additional significant investment to meet our growing customer demands,” said Penn’s CEO Richard Yarwood. “It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs.
“At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers.”